Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

Breast Cancer Research

Table 2 Univariate Cox proportional hazards model for disease-free survival and cancer-specific survival

	Disease-free survival			Cancer-specific survival
	P-value	Hazard ratio	95 % CI	P-value	Hazard ratio	95 % CI
Metformin
Metformin		1			1
Non-metformin versus metformin	0.05	1.50	1.0 to 2.25	0.02	1.69	1.07 to 2.68
Non-DM versus metformin	0.39	0.87	0.64 to 1.19	0.29	0.83	0.58 to 1.18
Age, years
≤50	0.652	0.97	0.87 to 1.09	0.023	0.83	0.73 to 0.96
BMI, kg/m2
High		1			1
Low versus high	0.141	1.24	0.94 to 1.64	0.362	1.17	0.84 to 1.64
Normal versus high	0.132	0.91	0.80 to 1.03	0.064	0.87	0.75 to 1.01
Tumor size, cm
T ≥2	<0.001	2.59	2.30 to 2.91	<0.001	3.10	2.68 to 3.59
Node metastasis
Node-positive	<0.001	2.79	0.49 to 3.13	<0.001	3.58	3.10 to 4.13
Estrogen receptor status
Positive	0.026	0.78	0.63 to 0.97	<0.001	1.85	1.62 to 2.11
Progesterone receptor status
Positive	0.001	0.72	0.60 to 0.87	<0.001	1.93	1.69 to 2.21
HER2 status
Positive	<0.001	1.44	1.28 to 1.62	<0.001	1.56	1.37 to 1.79
Chemotherapy
Yes	0.098	0.82	0.65 to 1.04	<0.001	0.38	0.31 to 0.46
Endocrine therapy
Yes	0.108	0.83	0.67 to 1.04	<0.001	1.78	1.56 to 2.03

ISSN: 1465-542X